Hdt Bio Corp
CAGE Code: 7YDE0
NCAGE Code: 7YDE0
Status: Active
Type: Commercial Supplier
Summary
Hdt Bio Corp is an Active Commercial Supplier with the Cage Code 7YDE0.
Address
1150 Eastlake Ave E Ste 200A
Seattle WA 98109-4413
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Micro Quill Software Publishing Inc University Of Washington Nursing Washington Packaging Supply, Inc. Energetic Music Inc Cossie Construction Co Nordine Mfg Co Archer Blower And Pipe Co Amplicom Computer Inc Dba Aci Micro Universal Colors Painting Co Environmental Review Ener-G-Foods Inc Bernth And Co Asi Sign Systems Smithkline Beecham Clinical Cascade Interactive Designs Inc Frank And Rosen University Plaza Hotel Darvin Electric Inc Whitestone Research Publications Prineas Stacy N Co
Frequently Asked Questions (FAQ) for CAGE 7YDE0
- What is CAGE Code 7YDE0?
- 7YDE0 is the unique identifier used by NATO Organizations to reference the physical entity known as Hdt Bio Corp located at 1150 Eastlake Ave E Ste 200A, Seattle WA 98109-4413, United States.
- Who is CAGE Code 7YDE0?
- 7YDE0 refers to Hdt Bio Corp located at 1150 Eastlake Ave E Ste 200A, Seattle WA 98109-4413, United States.
- Where is CAGE Code 7YDE0 Located?
- CAGE Code 7YDE0 is located in Seattle, WA, USA.
Contracting History for CAGE 7YDE0 Most Recent 25 Records
- 75A50123C00051
- Hdt Bio Corp - Aoi #21 Vaccine On Demand: R&D Use Of Lion-Reprna In Rapid Response Vaccine Development
- 21 Sep 2023
- Hdt Bio Corp - Aoi #21 Vaccine On Demand: R&D Use Of Lion-Reprna In Rapid Response Vaccine Development
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $749,000.00
- Department Of Health And Human Services (Hhs)
- 75N93022C00017
- Adaptable Rna-Based Antibody Platform For Protection Against Contemporary/Emerging Human Enteroviruses
- 1 Jul 2022
- Adaptable Rna-Based Antibody Platform For Protection Against Contemporary/Emerging Human Enteroviruses
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,499,422.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00052
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- 31 Aug 2022
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,970,058.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00052
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- 22 Mar 2023
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,970,058.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00052
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- 29 Jun 2021
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,252,444.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00052
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- 26 Oct 2023
- Covid-19. To Develop And Progress Hdt-301, A Replicon Rna Encoding Sars-Cov-2 Spike Protein Bound To Lipid Inorganic Nanoparticle (Lion) Formulation To Protect Against Covid-19, Through A Phase I Clinical Trial.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,970,058.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00028
- Sbir Phase I Topic 85
- 12 Aug 2020
- Sbir Phase I Topic 85
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,959.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00037
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza. Edited By Lnguyen_Nih On 11/19/2021 12:43:26
- 18 Nov 2021
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza. Edited By Lnguyen_Nih On 11/19/2021 12:43:26
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,629.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00037
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza
- 8 Apr 2020
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,629.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00037
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza.
- 17 Aug 2021
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,629.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00037
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza
- 21 Oct 2019
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,629.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00037
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza.
- 23 Aug 2019
- Rational Development Of A Combination Nanoparticle Adjuvant For Influenza.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,629.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00037
- Eo14042 - Rational Development Of A Combination Nanoparticle Adjuvant For Influenza.
- 13 Oct 2021
- Eo14042 - Rational Development Of A Combination Nanoparticle Adjuvant For Influenza.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,629.00
- Department Of Health And Human Services (Hhs)